Anti-complement intravitreal agents for geographic atrophy: A missed opportunity for European patients?

Abstract

Get full access to this article

View all access options for this article.

References

European Medicines Agency. Refusal of the marketing authorisation for Syfovre (pegcetacoplan) EMA/432931/2024. https://www.ema.europa.eu/en/medicines/human/EPAR/syfovre. Accessed on Nov 2, 2024

www.astellas.com/en/news/29531. Accessed on Nov 2, 2024

Heier

Lad

Holz

, et al. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. Lancet 2023 Oct 21; 402: 1434–1448. doi: https://doi.org/10.1016/S0140-6736(23)01520-9. PMID: 37865470.

Jaffe

Westby

Csaky

, et al. C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2/3 trial. Ophthalmology 2021 Apr; 128: 576–586. doi: https://doi.org/10.1016/j.ophtha.2020.08.027. Epub 2020 Sep 1. PMID: 32882310.

Khanani

Patel

Staurenghi

, et al. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. Lancet 2023 Oct 21; 402: 1449–1458. doi: https://doi.org/10.1016/S0140-6736(23)01583-0. Epub 2023 Sep 8. PMID: 37696275.

Ríos

Lövestam-Adrian

Plainis

, et al. Additional measures of macular function beyond visual acuity. Graefes Arch Clin Exp Ophthalmol 2024 Jun; 262: 1723–1736. doi: https://doi.org/10.1007/s00417-023-06272-1. Epub 2023 Nov 8. PMID: 37938378; PMCID: PMC11106142.

European Medicines Agency. Rhokiinsa (netarsudil) EMA/621772/2019. https://www.ema.europa.eu/en/medicines/human/EPAR/rhokiinsa. Accessed on Nov 2, 2024

European Medicines Agency. Committee for Medicinal Product for Human Use EMA/270690/2023. https://www.ema.europa.eu/en/search?search_api_fulltext=chmp%20rules&f%5B0%5D=ema_search_entity_is_document%3ADocument. Accessed on Nov 2, 2024